Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database

Background and purpose: Several clinical trials have indicated that the use of canagliflozin increases the risk of lower extremity amputation. Although the US Food and Drug Administration (FDA) has withdrawn its black box warning about amputation risk for canagliflozin, the risk still exists. We sou...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hui, Li, Zi-Ran, Zhang, Qian, Zhong, Ming-Kang, Yan, Ming-Ming, Qiu, Xiao-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971937/
https://www.ncbi.nlm.nih.gov/pubmed/36865915
http://dx.doi.org/10.3389/fphar.2023.1110575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971937/
https://www.ncbi.nlm.nih.gov/pubmed/36865915
http://dx.doi.org/10.3389/fphar.2023.1110575

Ejemplares similares